ScienceDex / Researcher record
Dwayne Forquer
- Leidos Biomedical Research, Inc. (no department on record)
From the FY2024 NIH awards this investigator leads as contact PI. The department is the award's.
- Top 1% Funded
- Early Career
NIH Funding · FY2024
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $21,434,446 | 1 | #111 |
| 2026 | $5,250,000 | 1 | #2,613 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2024 · selected1 record
- FY20261 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 16604152Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2024 award records by amount
NIH award records listing Dwayne Forquer as a PI. Multi-PI records show the full award amount for context.
- 261201500003I-P00012-26100071-1N01Contact PINCI CBIIT;EXPAND DATA COMMONS$21.4Maward amount
Award organization
Organizations that administered FY2024 awards listing Dwayne Forquer as a PI.
FY2024 award administered by Leidos Biomedical Research, Inc. (MD).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardLeidos Biomedical Research, Inc.
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024$5M Cumulative Funding
- 2024$10M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #111
- 2024Entered Top 25% NationallyRanked #111
- 2024Entered Top 10% NationallyRanked #111
- 2024Entered Top 5% NationallyRanked #111
- 2024Entered Top 1% NationallyRanked #111
- 2026$25M Cumulative Funding